A study of ABC008 for T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

illustrative image

Abcuro, Inc is starting a new clinical trial of ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL).

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) started in September 2022 and will continue throughout December 2023.

Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0.

Among the inclusion parameters are:

  • 18 years of age.
  • Has body mass index (BMI) ≤35 kg/m2.
  • Has a documented diagnosis of T LGLL. 

The location is the Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States. For more details and complete inclusion and exclusion criteria follow the link: https://ichgcp.net/clinical-trials-registry/NCT05532722.

Clinical Research News

Upcoming Clinical Trials